UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12B-25
SEC FILE NUMBER
000-26875
NOTIFICATION OF LATE FILING
CUSIP NUMBER
92764R 10 3
| (Check One): | [ ] Form 10-K | [ ] Form 20-F | [ ] Form 11-K |
| [X ] Form 10-Q | [ ] Form N-SAR | ||
For Period Ended: March 31, 2006
If the notification relates to a portion of the filing checked above, identify the Item (s) to which the notification relates:
PART I – REGISTRATION INFORMATION
Viral Genetics, Inc.
1321 Mountain View Circle
Azusa, CA 91702
PART II – RULES 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) [ X ]
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F or 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III – NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not be filed within the prescribed time period.
The Company was unable to complete and obtain required financials and other information without unreasonable effort and expense.
PART IV – OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
| Haig Keledjian | (626) 334-5310 |
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed. If answer is no, identify report(s).
[ X ] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof.
[ ] Yes [ X ] No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Viral Genetics, Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 15, 2006 | By: | /s/ Haig Keledjian |
Haig Keledjian President |
2
